Skip to content
DataLookout
Menu

H25-878 ORCHESNCT06937034

Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease

StatusCompleted
PhaseNot specified
SponsorAbbVie
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria revised Show 4 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Dec 2025 to Jul 28, 2025
    • Study sites: 4 to 5
    • Publications: details revised at 1 of 1 entry
  2. Notable Primary and study completion dates: May 2025 to Dec 2025
    • Study sites: 3 to 4
    v4
  3. Minor Study sites: 2 to 3v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Mean Base Infusion Rate
Timeframe: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).
Mean Low Infusion Rate
Timeframe: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).
Mean High Infusion Rate
Timeframe: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).

Arms and interventions

Participants with Parkinson's Disease

Advanced Parkinson Disease Patients treated with foslevodopa/foscarbidopa.

Sites

5 sites in 5 countries

Austria 1, Germany 1, Netherlands 1, Romania 1, Sweden 1